Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome
1 other identifier
interventional
106
0 countries
N/A
Brief Summary
Antibiotic lavage reduces bacterial contamination and decreases SSI infection rate. SSI leads to an immunocompromised situation, leaving unattended the neoplasm. It has been described that SSI may result in a worse oncologic outcome.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jan 2011
Typical duration for phase_3
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2015
CompletedFirst Submitted
Initial submission to the registry
March 23, 2015
CompletedFirst Posted
Study publicly available on registry
March 26, 2015
CompletedMarch 26, 2015
March 1, 2015
4.2 years
March 23, 2015
March 25, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Global survival
36 months after intervention
Secondary Outcomes (1)
Disease free survival
36 months after intervention
Study Arms (2)
Antibiotic lavage
EXPERIMENTALPeritoneal irrigation with Gentamycin - clndamycin solution
Normal saline lavage
ACTIVE COMPARATORPeritoneal irrigation with normal saline
Interventions
Peritoneal irrigation with gentamycin-clindamycin solution
Eligibility Criteria
You may qualify if:
- diagnosis of colon neoplasms
- plans to undergo an elective surgery with curative aims
You may not qualify if:
- preoperative diagnosis of chronic renal failure (because of the risk of nephrotoxicity associated with intraperitoneal gentamicin absorption)
- allergy to gentamicin or clindamycin.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jaime Ruiz-Tovar, MD, PhD
Hospital Rey Juan Carlos
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
March 23, 2015
First Posted
March 26, 2015
Study Start
January 1, 2011
Primary Completion
March 1, 2015
Study Completion
March 1, 2015
Last Updated
March 26, 2015
Record last verified: 2015-03